Diuretic use in renal disease

Nature Reviews Nephrology

Volumn 8, Issue 2, 2012, Pages 100-109

  Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ALBUMIN; AMILORIDE; AMLODIPINE; BENDROFLUMETHIAZIDE; BUMETANIDE; CHLOROTHIAZIDE; CHLORTALIDONE; CONIVAPTAN; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; HYDROFLUMETHIAZIDE; INDAPAMIDE; LISINOPRIL; LIXIVAPTAN; LOOP DIURETIC AGENT; MANNITOL; METOLAZONE; POLYTHIAZIDE; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; SODIUM; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; TRIAMTERENE; TRICHLORMETHIAZIDE; UNINDEXED DRUG; URIC ACID;

ASCITES; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DRUG DOSE TITRATION; DRUG TREATMENT FAILURE; ELECTROLYTE DISTURBANCE; EXTRACELLULAR FLUID; EXTRACELLULAR SPACE; HEART FAILURE; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; KIDNEY DISEASE; KIDNEY FAILURE; LIVER CIRRHOSIS; MONOTHERAPY; NEPHROTIC SYNDROME; OTOTOXICITY; OUTCOME ASSESSMENT; PHOTODERMATOSIS; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; WEIGHT GAIN;

DIURETICS; EXTRACELLULAR FLUID; HUMANS; KIDNEY DISEASES; TREATMENT OUTCOME;

EID: 84856474647     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.175     Document Type: Review

References (83)

1. Brenner, B.M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N.Engl. J.Med. 345, 861-869 (2001).
2. Bakris, G.L. et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch. Intern. Med. 163, 1555-1565 (2003). (Pubitemid 36835100)
3. Lewis, E.J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N.Engl. J.Med. 345, 851-860 (2001).
4. Berl, T. et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type2 diabetes and overt nephropathy. Ann. Intern. Med. 138, 542-549 (2003).
5. Brater, D.C. Diuretic therapy. N.Engl. J.Med. 339, 387-395 (1998). (Pubitemid 28363803)
6. Sica, D.A. & Gehr, T.W. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. Clin. Pharmacokinet. 30, 229-249 (1996).
7. Almeshari, K. et al. A volume-independent component to postdiuretic sodium retention in man. J.Am. Soc. Nephrol. 3, 1878-1883 (1993).
8. Ellison, D.H., Velázquez, H. & Wright, F.S. Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion. J.Clin. Invest. 83, 113-126 (1989). (Pubitemid 19048413)
9. Benet, L.Z. Pharmacokinetics/pharmacodynamics of furosemide in man: a review. JPharmacokinet. Biopharm. 7, 1-27 (1979). (Pubitemid 9148805)
10. Murray, M.D. et al. Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy 17, 98-106 (1997). (Pubitemid 27057122)
11. Brater, D. C. in The in vivo study of drug action: principles and applications of kinetic-dynamic modeling (eds van Boxtel, C. J., Holford, N. H. G. & Danhof, M.) 253-275 (Elsevier Science, Amsterdam, 1992).
12. Wilcox, C. S. New insights into diuretic use in patients with chronic renal disease. J. Am. Soc. Nephrol. 13, 798-805 (2002). (Pubitemid 34183949)
13. Kim, G. H. Long-term adaptation of renal ion transporters to chronic diuretic treatment. Am. J. Nephrol. 24, 595-605 (2004).
14. Shankar, S. S. & Brater, D. C. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am. J. Physiol. Renal Physiol. 284, F11-F21 (2003). (Pubitemid 35471281)
15. Beerman, B. Aspects on pharmacokinetics of some diuretics. Acta Pharmacol. Toxicol. 54 (Suppl. 1), 17-32 (1984).
16. van Olden, R. W. et al. Sensitivity of residual nephrons to high dose furosemide described by diuretic efficiency. Eur. J. Clin. Pharmacol. 47, 483-488 (1995).
17. Voelker, J. R. et al. Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int. 32, 572-578 (1987). (Pubitemid 17154747)
18. Rudy, D. W. et al. The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin. Pharmacol. Ther. 56, 39-47 (1994). (Pubitemid 24251563)
19. Brater, D. C. Pharmacokinetics of loop diuretics in congestive heart failure. Br. Heart J. 72 (2 Suppl.), S40-S43 (1994). (Pubitemid 24249726)
20. Murphy, C. A. & Dargie, H. J. Drug-induced cardiovascular disorders. Drug Saf. 30, 783-804 (2007). (Pubitemid 47347352)
21. Wilcox, C. S. et al. Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J. Lab. Clin. Med. 102, 450-458 (1983). (Pubitemid 13009620)
22. Kelly, R. A. et al. Response of the kidney to furosemide. II. Effect of captopril on sodium balance. Kidney Int. 24, 233-239 (1983). (Pubitemid 13043154)
23. Wilcox, C. S. et al. Na+, K+, and BP homeostasis in man during furosemide: effects of prazosin and captopril. Kidney Int. 31, 135-141 (1987). (Pubitemid 17006355)
24. Ellison, D. H. Diuretic drugs and the treatment of edema: from clinic to bench and back again. Am. J. Kidney Dis. 23, 623-643 (1994). (Pubitemid 24138415)
25. Loon, N. R., Wilcox, C. S. & Unwin, R. J. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int. 36, 682-689 (1989). (Pubitemid 19239561)
26. Ellison, D. H. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann. Intern. Med. 114, 886-894 (1991).
27. Sica, D. A. & Gehr, T. Diuretics in congestive heart failure. Cardiol. Clin. 7, 87-97 (1989). (Pubitemid 19070276)
28. Gehr, T. W. et al. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin. Pharmacol. Ther. 56, 31-38 (1994). (Pubitemid 24251562)
29. Hassan, Z. U., Kruer, J. J. & Fuhman, T. M. Electrolyte changes during craniotomy caused by administration of hypertonic mannitol. J. Clin. Anesth. 19, 307-309 (2007). (Pubitemid 46899490)
30. Weaver, A. & Sica, D. A. Mannitol-induced acute renal failure. Nephron 45, 233-235 (1987). (Pubitemid 17013828)
31. Knauf, H. & Mutschler, E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J. Cardiovasc. Pharmacol. 29, 367-372 (1997). (Pubitemid 27194723)
32. Wollam, G. L., Tarazi, R. C., Bravo, E. L. & Dustan, H. P. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am. J. Med. 72, 929-938 (1982). (Pubitemid 12086597)
33. Dargie, H. J., Allison, M. E., Kennedy, A. C. & Gray, M. C. High dosage metolazone in chronic renal failure. Br. Med. J. 4, 196-198 (1972).
34. Kidney Disease Outcomes Initiative (K/DOGI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney Dis. 43 (5 Suppl. 1), S1-S290 (2004).
35. Rahman, M. et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann. Intern. Med. 144, 172-180 (2006). (Pubitemid 46780689)
36. Vasavada, N. & Agarwal, R. Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int. 64, 1772-1779 (2003). (Pubitemid 37323706)
37. Dorhout Mees, E. J. Volaemia and blood pressure in renal failure: have old truths been forgotten. Nephrol. Dial. Transplant. 10, 1297-1298 (1995).
38. Calhoun, D. A. et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51, 1403-1419 (2008).
39. Sica, D. A. The risks and benefits of aldosterone antagonists. Curr. Heart Fail. Rep. 2, 65-71 (2005).
40. Santos, J. et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J. Hepatol. 39, 187-192 (2003). (Pubitemid 36920553)
41. Sica, D. A. Eplerenone: a new aldosterone receptor antagonist-are the FDA's restrictions appropriate. J. Clin. Hypertens. 4, 441-445 (2002). (Pubitemid 35469402)
42. Besseghir, K., Mosiq, D. & Roch-Ramel, F. Facilitation by serum albumin of renal tubular secretion of organic anions. Am. J. Physiol. 256, F475-F484 (1989).
43. Inoue, M. et al. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int. 32, 198-203 (1987). (Pubitemid 17122984)
44. Pichette, V., Geadah, D. & du Souich, P. The influence of moderate hypoalbuminemia on the renal metabolism and dynamics of furosemide in the rabbit. Br. J. Pharmacol. 119, 885-890 (1996). (Pubitemid 26366482)
45. Green, T. P. & Mirkin, B. L. Furosemide disposition in normal and proteinuric rats: urinary drug-protein binding as a determinant of drug excretion. J. Pharmacol. Exp. Ther. 218, 122-127 (1981). (Pubitemid 11033728)
46. Agarwal, R., Gorski, J. C., Sundblad, K. & Brater, D. C. Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome. J. Am. Soc. Nephrol. 11, 1100-1105 (2000). (Pubitemid 30367940)
47. Kirchner, K., Voelker, J. R. & Brater, D. C. Tubular resistance to furosemide contributes to the attenuated diuretic response in nephrotic rats. J. Am. Soc. Nephrol. 2, 1201-1207 (1992).
48. Danielsen, H., Pedersen, E. B., Madsen, M. & Jensen, T. Abnormal renal sodium excretion in the nephrotic syndrome after furosemide: relation to glomerular filtration rate. Acta Med. Scand. 217, 513-518 (1985). (Pubitemid 15019670)
49. Shapiro, M. D., Hasbargen, J., Hensen, J. & Schrier, R. W. Role of aldosterone in the sodium retention of patients with nephrotic syndrome. Am. J. Nephrol. 10, 44-48 (1990). (Pubitemid 20139501)
50. Esnault, V. L., Ekhlas, A., Delcroix, C., Moutel, M. G. & Nguyen, J. M. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J. Am. Soc. Nephrol. 16, 474-481 (2005). (Pubitemid 41725144)
51. Kunz, R., Friedrich, C., Wolbers, M. & Mann, J. F. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann. Intern. Med. 148, 30-48 (2008). (Pubitemid 351688350)
52. Chalasani, N. et al. Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients. J. Am. Soc. Nephrol. 12, 1010-1016 (2001). (Pubitemid 32378342)
53. Akcicek, F., Yalniz, T., Basci, A., Ok, E. & Mees, E. J. Diuretic effect of frusemide in patients with nephrotic syndrome: is it potentiated by intravenous albumin? Br. Med. J. 310, 162-163 (1995).
54. Fliser, D., Schröter, M., Neubeck, M. & Ritz, E. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int. 46, 482-488 (1994). (Pubitemid 24253057)
55. Asscher, A. W. Treatment of frusemide resistant oedema with metolazone. Clin. Trials J. 11, 134-139 (1974).
56. Sica, D. A. & Gehr, T. W. Diuretic use in stage five chronic kidney disease and end-stage renal disease. Curr. Opin. Nephrol. Hypertens. 12, 483-490 (2003). (Pubitemid 37083107)
57. Sica, D. A. Metolazone and its role in edema management. Congest. Heart Fail. 9, 100-105 (2003). (Pubitemid 36458710)
58. Allen, J. M., Hind, C. R. & McMichael, H. B. Synergistic action of metolazone with "loop" diuretics. Br. Med. J. (Clin. Res. Ed.) 282, 1873 (1981). (Pubitemid 11047757)
59. Tilstone, W. J., Dargie, H., Dargie, E. N., Morgan, H. G. & Kennedy, A. C. Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure. Clin. Pharmacol. Ther. 16, 322-329 (1974).
60. Rudy, D. W., Voelker, J. R., Greene, P. K., Esparza, F. A. & Brater, D. C. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann. Intern. Med. 115, 360-366 (1991).
61. van Olden, R. W., van Meyel, J. J. & Gerlag, P. G. Acute and long-term effects of therapy with high-dose furosemide in chronic hemodialysis patients. Am. J. Nephrol. 12, 351-356 (1992). (Pubitemid 23039910)
62. Bragg-Gresham, J. L. et al. Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am. J. Kidney Dis. 49, 426-431 (2007).
63. Sica, D. A. Diuretic-related side effects: development and treatment. J. Clin. Hypertens. (Greenwich) 6, 532-540 (2004).
64. Cocco, G., Iselin, H. U., Strozzi, C., Cesana, B. & Baumeler, H. R. Magnesium depletion in patients on long-term chlorthalidone therapy for essential hypertension. Eur. J. Clin. Pharmacol. 32, 335-338 (1987). (Pubitemid 17077176)
65. Schrier, R. W. Vasopressin and aquaporin 2 in clinical disorders of water homeostasis. Semin. Nephrol. 28, 289-296 (2008). (Pubitemid 351756521)
66. Morgan, D. B. & Davidson, C. Hypokalemia and diuretics: an analysis of publications. Br. Med. J. 280, 905-908 (1980).
67. Bakris, G. L. et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int. 58, 2084-2092 (2000).
68. Sica, D. A. The risks and benefits of aldosterone receptor antagonists. Curr. Heart Fail. Rep. 2, 65-71 (2005).
69. Korgaonkar, S. et al. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. Clin. J. Am. Soc. Nephrol. 5, 762-769 (2010).
70. Ljunghall, S. et al. Effects of bendroflumethiazide on urate metabolism during treatment of patients with renal stones. J. Urol. 127, 1207-1210 (1982). (Pubitemid 12088829)
71. Sica, D. A. & Schoolwerth, A. in The Kidney, 7th edn (eds Brenner, B. & Rector, F.) 637-662 (WB Saunders, Philadelphia, 2004).
72. Weinman, E. J., Eknoyan, G. & Suki, W. N. The influence of the extracellular fluid volume on the tubular reabsorption of uric acid. J. Clin. Invest. 55, 283-291 (1975).
73. Menè, P. & Punzo, G. Uric acid: bystander or culprit in hypertension and progressive renal disease? J. Hypertens. 26, 2085-2092 (2008).
74. So, A. & Thorens, B. Uric acid transport and disease. J. Clin. Invest. 120, 1791-1799 (2010).
75. Isakova, T. et al. Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. Nephrol. Dial. Transplant. 26, 1258-1265 (2011).
76. Reilly, R. F., Peixoto, A. J. & Desir, G. V. The evidence-based use of thiazide diuretics in hypertension and nephrolithiasis. Clin. J. Am. Soc. Nephrol. 5, 1893-1903 (2010).
77. Bolland, M. J. et al. The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporos. Int. 18, 479-486 (2007). (Pubitemid 46354921)
78. Addo, H. A., Ferguson, J. & Frain-Bell, W. Thiazide-induced photosensitivity: a study of 33 subjects. Br. J. Dermatol. 116, 749-760 (1987). (Pubitemid 17075394)
79. Wall, G. C., Bigner, D. & Craig, S. Ethacrynic acid and the sulfa-sensitive patient. Arch. Intern. Med. 163, 116-117 (2003). (Pubitemid 36091610)
80. Rybak, L. P. Ototoxicity of loop diuretics. Otolaryngol. Clin. North Am. 26, 829-844 (1993). (Pubitemid 23292840)
81. Sica, D. A. Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diuretics. Congest. Heart Fail. 9, 287-292 (2003).
82. Allen, L. A. et al. Continuous versus bolus dosing of Furosemide for patients hospitalized for heart failure. Am. J. Cardiol. 105, 1794-1797 (2010).
83. Felker, G. M. et al. Diuretic strategies in patients with acute decompensated heart failure. N. Engl. J. Med. 364, 797-805 (2011).